<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2282">
  <stage>Registered</stage>
  <submitdate>19/01/2009</submitdate>
  <approvaldate>19/01/2009</approvaldate>
  <nctid>NCT00859391</nctid>
  <trial_identification>
    <studytitle>Effects of Gluten Digestion With ALV003</studytitle>
    <scientifictitle>A Phase 0 Study in Subjects With Well Controlled Celiac Disease to Assess the Effects of Gluten Digestion With ALV003 (a Protease Enzyme) in Vitro</scientifictitle>
    <utrn />
    <trialacronym>0801</trialacronym>
    <secondaryid>ALV0801</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Celiac Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Autoimmune diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Human Genetics and Inherited Disorders</conditioncode1>
      <conditioncode2>Other human genetics and inherited disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>1 - Active - This group received gluten pre-treated with ALV003

2 - Placebo - This group received Gluten pre-treated with placebo.

</interventions>
    <comparator />
    <control />
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The clinical response by symptom measurement before and after oral challenge</outcome>
      <timepoint>Day 1 and Day 6</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>The immune response measured by ELISPOT testing and celiac disease serology</outcome>
      <timepoint>Prior to and post 3-day gluten challenge</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Describe the immunotoxic epitope profile of gluten digests with ALV003 compared with placebo</outcome>
      <timepoint>Day 1 and Day 14</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Age 18-75 years

          -  Well controlled Celiac Disease without flare in symptoms for the past 8 weeks

          -  History of biopsy proven Celiac Disease

          -  Able and willing to complete a symptom diary for 3 days prior and through 3 days post
             gluten challenge

          -  Been on a gluten free diet for 8 weeks prior to study entry

          -  Have normal celiac serology (anti- tTG level of &lt;20 units/mL)</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Uncontrolled complications of celiac disease which in the opinion of the Investigator
             would impact their immune response, or pose an increased risk to the subject.
             (example: like type 1 diabetes or other autoimmune disease)

          -  Pregnant or breast feeding women, subjects of childbearing potential to use two
             methods of contraception

          -  Concomitant medications such as over the counter digestive enzymes, immunosuppressive
             therapies, anticoagulants, NSAIDs. Chronic medications for well-controlled chronic
             conditions are allowed.

          -  Clinically significant abnormal lab values, as determined by the PI:

          -  Untreated or active peptic ulcer disease, esophagitis, motility disorders or any
             gastrointestinal diseases.

          -  Positive pregnancy test within 7 days prior to study drug administration

          -  Known allergy or hypersensitivity to E.coli or E.coli derived proteins</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Phase 0</phase>
    <anticipatedstartdate />
    <actualstartdate>1/05/2008</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>20</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/06/2008</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Nucleus Networks Limited - Melbourne</hospital>
    <postcode>3004 - Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Alvine Pharmaceuticals Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a Phase 0, Double-blind study that will assess the effect of in vitro treatment of
      gluten with ALV003 or with placebo when ingested by CD Subjects.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00859391</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Gregor Brown, MD</name>
      <address>The Alfred</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>